Medication Optimization Using Pharmacogenetic Testing and the G-DIG to Reduce Polypharmacy in a M… (NCT03468309) | Clinical Trial Compass
CompletedNot Applicable
Medication Optimization Using Pharmacogenetic Testing and the G-DIG to Reduce Polypharmacy in a Mental Health Population
United States53 participantsStarted 2018-01-01
Plain-language summary
Use of polypharmacy has significantly increased over the past two decades, which has unproven clinical benefit and is associate with an increased the risk of adverse side effects. Pharmacogenetic assays, such as the Genecept® Assay, have the purported benefit of being able to predict response(s) to specific medication based on genetic markers. Thus, this study is a 12-week open-label, naturalistic study of the provision of pharmacogenetic testing and a computerized decision tool for providers to determine the potential efficacy of the assay to reduce polypharmacy and improve patient outcomes.
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Currently receiving outpatient care for mental health diagnosis at VA Puget Sound Health Care System (VA PSHCS) and referred by sub-investigator on listed for study
✓. Currently experiencing a sub-optimal medication response as assessed by either continue symptoms or medication side effects; which in the opinion of their treating provider would indicate or warrant a change in medications
✓. Currently prescribed at least five medications; two being for a mental health diagnosis OR one mental health medication prescribed for mental health diagnosis and one for mediating side effects related to the medication prescribed for the mental health diagnosis.
✓. Between the ages of 18-75.
Exclusion criteria
✕. Any mental health or physical health diagnosis, which in the opinion of their treating prescriber would prevent them from being compliant on a medication regimen or being able to complete the study measures.
✕. Current/active diagnosis of severe alcohol or drug use disorder
✕. Serious medical or mental health symptoms requiring immediate stabilization and/or hospitalization
What they're measuring
1
Clinical Global Impression
Timeframe: Baseline and 12-weeks
Trial details
NCT IDNCT03468309
SponsorSeattle Institute for Biomedical and Clinical Research